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Available online xxxxBackground: The phosphodiesterase-5 inhibitor (PDE5) sildenaﬁl has emerged as a promising treatment for
preeclampsia (PE). However, a sildenaﬁl trial was recently halted due to lack of effect and increased neonatal
morbidity.
Methods: Ex vivo dual-sided perfusion of an isolated cotyledon and wire-myography on chorionic plate arteries
were performed to study the effects of sildenaﬁl and the non-selective PDE inhibitor vinpocetine on the response
to the NO donor sodium nitroprusside (SNP) under healthy and PE conditions. Ex vivo perfusionwas also used to
study placental transfer of sildenaﬁl in 6 healthy and 2 PE placentas. Furthermore, placental mRNA and protein
levels of eNOS, iNOS, PDE5 and PDE1 were quantiﬁed.
Findings: Sildenaﬁl and vinpocetine signiﬁcantly enhanced SNP responses in chorionic plate arteries of healthy,
but not PE placentas. Only sildenaﬁl acutely decreased baseline tension in arteries of both healthy and PE pla-
centas. At steady state, the foetal-to-maternal transfer ratio of sildenaﬁl was 0·37 ± 0·03 in healthy placentas
versus 0·66 and 0·47 in the 2 PE placentas. mRNA and protein levels of PDE5, eNOS and iNOS were comparable
in both groups, while PDE1 levels were lower in PE.
Interpretation: The absence of sildenaﬁl-induced NO potentiation in arteries of PE placentas, combined with the
non-PDE-mediated effects of sildenaﬁl and the lack of PDE5upregulation in PE, argue against sildenaﬁl as the pre-
ferred drug of use in PE. Moreover, increased placental transfer of sildenaﬁl in PE might underlie the neonatal
morbidity in the STRIDER trial.
Fund: This study was funded by an mRACE Erasmus MC grant.







Suboptimal development of the placenta results in serious preg-
nancy complications such as preeclampsia (PE) and foetal growth re-
striction (FGR), that contribute signiﬁcantly to perinatal and maternal
morbidity and mortality [1,2]. Besides increasing the risk of adverse
events during pregnancy, placenta-related diseases have lifelongdicine, Room Ee-1418, Erasmus
dam, the Netherlands.
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oekhuizen, K.M. Mirabito Co
https://doi.org/10.1016/j.ebioconsequences for the health of both mother and child. For example, PE
increases the maternal risk of developing cardiovascular disease [3,4]
and can cause persistent vascular dysfunction in the systemic and pul-
monary circulation of the offspring [5], whereas preterm birth and low
birthweight greatly increase the risk of cardiopulmonary morbidity
and neurodevelopmental impairment later in life [6,7]. Currently, PE
treatment is aimed at symptom relief and prevention of further compli-
cations in an attempt to prolong pregnancy until term.Many antihyper-
tensive agents have been studied over the years, but they at most
temporarily stabilise the clinical manifestations of PE, without directly
targeting placental hypoperfusion [8,9]. The only cure is termination-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
lafella, et al., Placental effects and transfer of sildenaﬁl in healthy
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Research in context
Evidence before this study
The past years the phosphodiesterase-5 inhibitor (PDE5) sildenafil
has been of interest as a potential new therapy for preeclampsia
(PE). Animal studies using PE models showed promising results,
as sildenafil treatment improved foetal outcome and abolishedma-
ternal PE symptoms, by increasing blood flow to the uterus and
hence the placenta. However, a large clinical trial (the STRIDER
study) was recently halted because of likely futility to show bene-
ficial effects and increased neonatal morbidity in one of the co-
horts. It has been shown that sildenafil passes the placenta and
has vasodilator effects on foetoplacental vasculature, both in the
isolated perfused cotyledon and in isolated chorionic plate vessels
of healthy placentas. However, knowledge is lacking regarding its
effect and transfer in PE placentas.
Added value of this study
Although sildenafil potentiated nitric oxide-mediated vasodilation
in chorionic plate arteries obtained from healthy placentas, this
beneficial effect was not seen in PE placentas. Yet, sildenafil de-
creased baseline tension in arteries of both healthy and PE pla-
centas in a PDE5-independent manner. Our study additionally
showed that placental transfer of sildenafil was increased in two
preterm PE placentas versus six healthy placentas. Furthermore,
PDE5 gene - and protein levels were not upregulated in PE
placentas.
Implications of all the available evidence
Although sildenafil seems to increase uterine (and therefore pla-
cental) perfusion, its inability to potentiate nitric oxide, its PDE5-
independent dilator effect, and the absence of PDE5 upregulation
in PE argue against sildenafil as the preferred drug for treating
this condition, especially when its placental transfer is indeed in-
creased in PE. These findings togethermay help to explain its futil-
ity and the neonatal toxicity in STRIDER.
2 E. Hitzerd et al. / EBioMedicine xxx (2019) xxxof pregnancy to deliver the placenta, which often leads to preterm birth
of the foetus. Therefore, developing new treatment options to treat PE
and safely prolong pregnancy is of great importance.
Although the aetiology of PE remains largely unknown, itﬁnds its or-
igin in early pregnancy with suboptimal placentation, characterised by
increased placental vascular resistance and hypoperfusion, leading to
systemic endothelial dysfunction [10–12]. One of the key features of
this endothelial dysfunction is a decreased activity of the nitric oxide
(NO) pathway [13–15]. NO acts as an important vasodilator, synthe-
sised by a family of nitric oxide synthases (NOS), predominantly endo-
thelial NOS (eNOS) and inducibleNOS (iNOS). NOS enzymes are present
in various cell types including endothelial cells and foetal trophoblasts,
and stimulation of these enzymes (e.g., by endothelial shear stress or
oestrogen) results in the production of NO through catalysis of L-
arginine. By activating soluble guanylate cyclase (sGC), NO induces an
increase in production of cyclic guanosine 3′,5′-monophosphate
(cGMP), leading to vasodilation through closure of Ca2+ channels
[13,14].
Besides regulation of vascular tone, NO also plays an important role
in cytotrophoblast invasion of the receptive endometrium and subse-
quent spiral artery remodelling during early pregnancy [16]. Through-
out normal pregnancy there is an increase in maternal plasma levelsPlease cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioof NO [17], as well as NO-stimulating factors such as vascular endothe-
lial growth factor and placental growth factor [18,19]. However, in
women with PE these plasma levels are signiﬁcantly lower [17,20,21].
Sildenaﬁl, as a phosphodiesterase-5 (PDE5) inhibitor, enhances vasodi-
lation mediated by the NO pathway, by inhibiting degradation of active
cGMP into inactive GMP by PDE5. Sildenaﬁl is currently approved for
the treatment of erectile dysfunction and pulmonary hypertension
[22]. In PE animal models, sildenaﬁl improved foetal outcome and di-
minished maternal symptoms by increasing blood ﬂow to the uterus
[23,24].
Because of its potential to improve placental hypoperfusion by in-
creasing systemic vasodilation, sildenaﬁl has been considered for the
treatment of PE and FGR over the last years. However, an international
consortium of large multi-centre randomised controlled trials (the
STRIDER study), investigating the effect of sildenaﬁl compared to pla-
cebo on pregnancy outcome in extreme FGR due to placental insufﬁ-
ciency [25,26], was recently halted due to lack of beneﬁcial effects in
the ﬁrst two cohorts [27,28] and an increase in neonatal morbidity
and mortality in the treatment group of one cohort [28,29]. These re-
sults emphasise the importance of taking into account the possible ef-
fects that maternal medication use can have on the foetus. When
considering drugs for treatment in human pregnancy, it is essential to
know the trans-placental transfer and effects on the placental vascula-
ture. Hence, besides transfer, study of the placenta can give insight
into vascular effects of sildenaﬁl in the foetus. Dual ex vivo perfusion
of a single placental cotyledon is the only reliable experimental method
to study drug transfer across the human placental barrier to date [30].
With this model Russo et al. recently showed that sildenaﬁl crosses
the placenta of healthy term pregnancies [31], however to our knowl-
edge this has never been performed in PE placentas. The aim of our
study is to evaluate the effects of sildenaﬁl onNO-mediated vasodilation
in the foetoplacental vasculature, to evaluate placental transfer in
healthy and PE placentas, and to study placental expression levels of
components of the NO pathway under healthy and PE conditions. This
could help to provide a possible explanation for the negative ﬁndings
obtained with sildenaﬁl in the above-mentioned clinical trials. Under-
standing these negative ﬁndings will be helpful for the development
of future therapies.2. Methods
2.1. Patients and setting
The study received exemption for approval from the local institu-
tional Medical Ethics Committee according to the Dutch medical Re-
search with Human Subjects Law (MEC-2016-418 and MEC-2017-
418), and all patients gave written consent prior to donating their
placenta. Randomly selected placentas of uncomplicated singleton
pregnancies and of patients with early onset PE (diagnosis before
34 + 0 weeks of gestation) were collected immediately after
delivery at Erasmus University Medical Center, Rotterdam, the
Netherlands. Because it is generally believed that late onset PE (diag-
nosis from 34 + 0 weeks of gestation onwards) has a different path-
ophysiological mechanism than early onset PE, being more a
maternal rather than a placental syndrome [32], and also showing
clear histopathological differences in the placenta [33], late onset PE
was excluded from the current study. Further exclusion criteria
were retained placenta, viral infections (HIV, hepatitis B, Zika), the
presence of foetal congenital abnormalities on ultrasound, participa-
tion in the STRIDER study and for the healthy controls any form of
diabetes. Baseline characteristics such as maternal age, medical his-
tory, obstetrical history, use of medication, blood pressure, mode of
delivery, gestational age at delivery, foetal sex, foetal weight, placen-
tal weight and pregnancy complications were obtained from the dig-
ital medical ﬁles.lafella, et al., Placental effects and transfer of sildenaﬁl in healthy
m.2019.06.007
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Second order branches of chorionic plate arteries were identiﬁed,
carefully dissected and stored overnight in cold, oxygenated Krebs-
Henseleit buffer. The next morning the vessels were cut into segments
of 2 mm and mounted in 6mL organ baths (Danish Myograph Technol-
ogy, Aarhus, Denmark), ﬁlled with Krebs-Henseleit buffer at 37 °C and
gassed with 95% O2–5% CO2. Tension was normalised to 90% of the esti-
mated diameter at 100mmHg effective transmural pressure. Maximum
contractile responses were determined using 100 mmol/L potassium
chloride (KCl). After washout of the KCl, precontraction was elicited
using the thromboxane A2 agonist U46619 (10 nmol/L) resulting in
75–100% of the contraction induced by 100 mmol/L KCl. Subsequently,
a concentration-response curve (CRC) was constructed for SNP
(0·001–100 μmol/L). To study the effect of PDE inhibition on NO-
mediated vasodilation, vessel segments were either pre-incubated for
30 min with sildenaﬁl (1 μmol/L), the non-selective PDE inhibitor
vinpocetine (10 μmol/L) or without additives as control.
2.3. Placental perfusion setup
The perfusion model used in our study has been adapted from the
model previously described by Schalkwijk et al. [34] It consists of a per-
fusion chamber, two peristaltic roller pumps, heating devices and a
water bath (37 °C). The maternal and foetal perfusion media consisted
of Krebs-Henseleit buffer (in mmol/L: NaCl 118, KCl 4·7, CaCl2 2·5,
MgSO4 1·2, KH2PO4 1·2, NaHCO3 25 and glucose 8·3), supplemented
with heparin 5000 IU (0·5 mL/L) and aerated with 95% O2–5% CO2.
After selecting an intact cotyledon, the foetal circulationwas established
by cannulating the chorionic artery and corresponding vein. Flow rate
was carefully increased to 3 or 6mL/min, depending on the experiment.
When this was successful, the cotyledon was cut from the placenta and
placed inside the perfusion chamber. Maternal circulation (ﬂow rate
12 mL/min) was created by placing four blunt cannulas in the
intervillous space through remnants of the spiral arterioles. Venous out-
ﬂowwas collected in a reservoir underneath the cotyledon and run back
to the maternal reservoir. A placental washout period of approximately
45 min was performed before starting an experiment. Changes in pres-
sure were continuously measured by pressure transducers and re-
corded throughout the experiment using acquisition software (Biopac,
Goleta, CA, USA).
2.4. Placental vasoreactivity
To study the effect of sildenaﬁl on the foetal vascular bed of the pla-
centa, NO-mediated vasodilation was tested in the absence or presence
of sildenaﬁl. When a stable baseline pressure was reached after the
washout period, sildenaﬁl (500 ng/mL)was added to the foetalmedium
in half of the placentas that were randomly selected. After approxi-
mately 15min 1 μmol/L serotonin (5-HT)was administered to the foetal
circulation to preconstrict the vasculature. Subsequently, the NO donor
sodiumnitroprusside (SNP)was used to induce vasodilation (1 μmol/L).
Changes in placental vascular resistance were used to assess themagni-
tude of the vasodilator response.
2.5. Placental transfer of sildenaﬁl
To study placental transfer, sildenaﬁl was administered to the ma-
ternal circulation at start of the experiment in a concentration of
500 ng/mL, the maximal tolerated concentration in humans [35]. Sys-
tem adherence of sildenaﬁl was tested by adding the drug to the perfu-
sion system in the absence of a placenta. At t=0, antipyrine (100mg/L)
was added to the maternal buffer as a positive control of passive diffu-
sion across the placental barrier and to prove adequate overlap between
maternal and foetal circulations, and the macromolecule FITC-dextran
(40 kDa, 36mg/L)was added to the foetal buffer as amarker of integrityPlease cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioof the capillary bed. Samples of the maternal and foetal buffer were
taken at seven set time points, and immediately stored at−80 °C.
2.6. Quality control
The placenta was excluded from further analysis when ﬂuid leakage
from the foetal circulation exceeded 3 mL/h, the foetal-to-maternal
(F/M) ratio of antipyrine was b0·75 at t = 180, or the maternal-to-
foetal (M/F) ratio of FITC-dextran was N0·03 at t= 180 [36].
2.7. Analysis of antipyrine and FITC-dextran
Antipyrine concentration was analysed by ﬁrst deproteinising the
samples with perchloric acid 6%. After this, a mixture of 0·2 mg/mL
NaNO2 and 0·6%H2SO4was added in a 1:1 ratio to formnitroantipyrine.
Usingultraviolet–visible spectroscopy (ShimadzuUV-1800), absorption
at 350 nmwasmeasured. For analysis of FITC-dextran, ﬂuorescencewas
measured using a Multiwell Plate Reader (Victor X4 Perkin Elmer, exci-
tation/emission 485/519 respectively).
2.8. LC-MS analysis of sildenaﬁl
The concentration of sildenaﬁl in placental perfusate was measured
with a FDA validated liquid chromatography-mass spectrometry
method (LC-MS), using ThermoTQSVantage LC-MS/MS for the analysis.
Column 2·1 × 100mm Waters Acquity CSH C18 1·7um. The mobile
phase A consisted of 2 mM ammonium acetate in 0·1% formic acid in
water. The mobile phase B consisted of 2 mM ammonium acetate in
0·1% formic acid in LC-MS methanol. Flow rate was 0·5 mL/min. The
mobile phase composition changed linearly during analysis in a per-
centage mobile phase A (from 80% to 0) and B (from 2% to 100%).
Total analysis time was four min. The injected volume was 10 μL. Inter-
nal standard was vardenaﬁl. The method was validated according to
FDA guidelines between 2 and 1000 μg/L for sildenaﬁl and 2–500 μg/L
for desmethylsildenaﬁl [37].
2.9. qPCR
Within 20 min after delivery of the placenta pieces of tissue were
dissected from both the foetal and maternal side of the placenta and
snap frozen in liquid nitrogen. For RNA extraction, small pieces of tissue
were homogenised in RLT lysis buffer (Qiagen, Venlo, the Netherlands)
with β-mercaptoethanol. After proteinase K treatment (Invitrogen,
Breda, the Netherlands) for ten minutes at 55 °C, total RNA was ex-
tracted using the RNeasy Fibrous Tissue Mini Kit (Qiagen). RNA was
eluted in RNase free water, and concentration and purity were assessed
on a NanoDrop1000 Spectrophotometer (Thermo Fisher Scientiﬁc,
Bleiswijk, the Netherlands). Complimentary DNA (cDNA) was synthe-
sised from 0·5 μg RNA template with the SensiFast cDNA Synthesis Kit
(Bioline, London, UK) according to the manufacturer's instructions.
This cDNA was used for quantitative PCR (qPCR) using the SYBR Green
qPCR Kit (Bioline, London, UK) and speciﬁc primer pairs on a CFX-96
light cycler (Bio-Rad, Hercules, CA, USA). qPCR was performed with
the following conditions: initial denaturation at 95 °C for eight min
and 30 s, followed by 40 cycles comprising 15 s at 95 °C, and 60 s at
60 °C. Target genes were normalised against the reference genes β-
actin and Peptidylprolyl Isomerase A (PPIA) and relative gene expres-
sion was calculated by the ΔΔCt method. A melt curve was run for
each gene to conﬁrm ampliﬁcation of a single PCR product. The speciﬁc
primer pairs are listed in Table S1.
2.10. Western blot analysis
Snap frozen pieces of placental tissue were homogenised in RIPA
buffer (150 mM NaCl, 1% Triton X-100, 0·5% Sodium Deoxycolate,
0·1% SDS, 50 mM Tris pH 8·0) with protease and phosphataselafella, et al., Placental effects and transfer of sildenaﬁl in healthy
m.2019.06.007
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at 4 °C, 13000 rpm for three min. Supernatant was collected of each
sample, and total protein concentration was determined with the
Pierce® BCA Protein Assay Kit (Thermo Fisher Scientiﬁc). Per sample
50 μg of total protein was loaded onto a 4–15% mini-protean TGX gel
(Bio-Rad). Samples were resolved at 80 V for 20 min followed by
110 V for 60 min (PDE5A) or 120 min (eNOS). Transfer of proteins to
the membrane was done on ice for one h at 110 V. Subsequently, after
blocking in tris-buffered saline + 5% BSA for one h, the membranes
were incubated with anti-PDE5A 1:1000 (Abcam Cat# ab64179, RRID:
AB_1566572, 1 mg/mL), anti-eNOS 1:500 (BD Biosciences Cat#
610296, RRID:AB_397690, 250 μg/mL), or anti-iNOS 1:1000 (Abcam
Cat# ab182640, 1 mg/mL), and anti-β-actin 1:1000 (Abcam Cat#
ab8229, RRID:AB_306374) for 1.5 h at room temperature. Hereafter,
the membranes were incubated with 1:15000 diluted ﬂuorescently-
labelled secondary antibody for one h. Bands were visualised by the
Odyssey® Infrared Imaging System, and analysed in Image Studio Lite
(LI-COR Biosciences). The density of each band was normalised to β-
actin and displayed as arbitrary unit (AU) value.
2.11. Statistical analysis
A power analysis was performed based on our previous experience
with wire-myography experiments [38]. Based on the same standard
deviation, at an α level of 0.05 and with statistical power at 80%, a de-
rived minimum sample size of 6 per group was determined. Because
of skewed distributions, non-parametric tests were applied. Statistical
analysis was performed with SPSS (version 21, SPSS Chicago, IL, USA)
and GraphPad Prism (version 5, 2007, La Jolla, CA, USA) on Windows.
Statistical analysis between groups was performed using either a
Mann-Whitney U test or Wilcoxon matched pairs test for two groups,
and a Kruskal-Wallis test or a Friedman test for repeated measures
with a Dunn's post-hoc test for three groups where appropriate.
Log10-transformed SNP values at which the half-maximal response oc-
curred (pEC50) were individually estimated with sigmoid curve ﬁtting
software (GraphPad Prism 5). Data are displayed as median (interquar-
tile range) or mean ± SEM unless stated otherwise. A p-value b0·05
was considered to be statistically signiﬁcant.
3. Results
3.1. Wire-myography experiments
Chorionic plate arteries of 12 healthy and six PE placentas were dis-
sected and mounted into Mulvany wire-myographs. Clinical character-
istics can be found in Table S2. For analysing the CRC of SNP, ﬁve healthy
and one PE placentas were excluded because of severe spontaneous
vasomotion, making it impossible to analyse SNP effects. Sildenaﬁl
acutely decreased baseline tension vs. control in vessel segments of
both healthy (p = 0·01) and PE placentas (p = 0·05) during the incu-
bation period (Fig. 1a). Such effects were not seen for vinpocetine. SNP
fully relaxed U46619-preconstricted vessels in all conditions, and both
sildenaﬁl and vinpocetine enhanced (p = 0·02) the SNP response in
healthy vessel segments (Fig. 1b and 1c and Table 1). No such potentia-
tion was seen in vessel segments obtained from PE placentas. The max-
imum effect of SNP was unaltered by PDE inhibition.
3.2. Placental vasoreactivity
A total of 26 (18 healthy and eight PE) placentas were included in
the analysis. Clinical characteristics of these placentas can be found in
Table S3. As expected, the gestational age and birth - and placental
weight were lower in PE placentas, and they were associated with a
higher maternal blood pressure. Baseline pressure at the start of the ex-
perimentwas signiﬁcantly lower in placentas fromPEpregnancies com-
pared to healthy placentas (p = 0·03) (Table 2). Moreover, the 5-HT-Please cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioinduced pressure increase was lower in the PE group (p = 0·07). SNP
reversed the 5-HT-induced pressure increases, although signiﬁcantly
less in PE placentas (p = 0·02) compared to controls. Under no condi-
tion did sildenaﬁl signiﬁcantly improve the SNP response (Table 2).
3.3. Placental transfer of sildenaﬁl
Of the received placentas, a total of six out of 12 healthy and two out
of 11 PE placentasmet the quality control criteria, and were included in
the analysis. For healthy term placentas the success rate of ~50% is
higher than the average reported in literature [36]. To our knowledge
there are no previous reports on success rate of perfusion experiments
in preterm PE placentas.
All included placentas showed good overlap of the maternal and
foetal circulations with a F/M ratio for antipyrine of N0·75 (Fig. S1).
Table 3 shows the clinical characteristics of the included placentas.
All women underwent elective caesarean section, because of previous
caesarean section (four), previous shoulder dystocia (one) and intra-
cranial hematoma that contra-indicated vaginal delivery (one). Both
PE patients underwent a caesarean section because of maternal ill-
ness and foetal distress. As expected, the placentas from PE pregnan-
cies were born at an earlier gestational age (~32 weeks) and
associated with a higher maternal blood pressure and a lower birth
- and placental weight. The six healthy placentas were perfused at
a foetal ﬂow rate of 3 or 6 mL/min (n = 3 for each). Since there
were no signiﬁcant differences in transfer ratios of antipyrine and sil-
denaﬁl between the two ﬂow rates (Fig. S2), the results have been
combined. Fig. 2a shows the placental transfer of sildenaﬁl in healthy
placentas. The transfer rate of sildenaﬁl was highest in the ﬁrst hour,
and after ~90 min an equilibrium between the maternal and foetal
circulations had been reached. After 180 min of perfusion the F/M
ratio of sildenaﬁl was 0·37 ± 0·03. In the two PE placentas the pla-
cental transfer of sildenaﬁl followed a similar pattern (Fig. 2b), and
the F/M ratios in these two placentas were the highest of all pla-
centas studied (0·66 and 0·47, Fig. 2c). At the end of the experi-
ment, under steady state conditions, in healthy placentas 43 ± 3%
and 16 ± 1% of the total amount of added sildenaﬁl were recovered
in the maternal and foetal compartments, respectively, while in PE
conditions these percentages amounted to 36 ± 8% and 20 ± 1%.
This implies that, under healthy conditions, after three hours of per-
fusion 59% of the total starting amount of sildenaﬁl could be re-
trieved in the perfusion buffers. After running the system without a
placenta, a comparable 52% (mean of two measurements) was re-
trieved at the end of the experiments, indicating that the loss of sil-
denaﬁl is largely caused by tube adherence.
3.4. mRNA and protein expression
Snap frozen samples of 12 healthy and seven PE placentaswere used
to determine mRNA expression of eNOS, iNOS, PDE4A, PDE10A, PDE5A
and PDE1A using qPCR. Clinical characteristics can be found in
Table S4. Of all measured PDEs, PDE5A displayed the highest expression
(Fig. S3). For PDE5A and eNOS, expression on the maternal side was
higher than on the foetal side in healthy and PE placentas (Fig. 3).
PDE1A expression was higher on the foetal side than maternal side in
both conditions, although signiﬁcance was reached in healthy placentas
only (Fig. 3). For iNOS, expression on the foetal side was higher than on
the maternal side in PE placentas only (Fig. 3). However, it should be
noted that iNOS expression was extremely low and highly variable,
and was also not detectable at protein level. No statistically signiﬁcant
differences between patient groups were observed, with the exception
of PDE1A,whichwas lower on the foetal side of PE vs. healthy placentas.
In agreement with the gene expression data, protein expression
of PDE5A and eNOS did not differ between patient groups (Figs. S4
and S5).lafella, et al., Placental effects and transfer of sildenaﬁl in healthy
m.2019.06.007
Fig. 1.Wire-myography experiments. Panel a, decrease of baseline tension in response to PDE inhibitors. Panels b and c, effect of PDE inhibition with sildenaﬁl or vinpocetine on SNP-
mediated relaxation of chorionic plate vessels of seven healthy (b) and ﬁve PE (c) placentas. Data (mean ± SEM) are expressed as % of U46619 precontraction. *p b 0·05; **p b 0.01
(Friedman test for repeated measures).
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This study shows that sildenaﬁl decreased baseline pressure in iso-
lated chorionic plate arteries from both healthy and PE placentas. Yet,
it enhanced the relaxant effects of the NO donor SNP only in chorionic
plate vessels obtained from healthy placentas, and not in vessels from
PE placentas, nor when applied at the foetal side in the cotyledon
setup. A similar enhancement was observed for the non-selective PDE
inhibitor vinpocetine in chorionic plate vessels obtained from healthyPlease cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioplacentas, although this drug did not decrease baseline pressure. Pla-
cental transfer of sildenaﬁl was highest in the two PE placentas. Finally,
while PDE5 expression was higher at the maternal side of the placenta
versus the foetal side, its expression was not changed in PE, nor was
the expression of other PDEs.
Sildenaﬁl has been proposed to enhance NO availability in FGR and
PE, and may thus improve endothelial function and placental perfusion
[39]. Exactly this effect was observed when studying NO-induced re-
sponses in isolated chorionic plate arteries obtained from healthylafella, et al., Placental effects and transfer of sildenaﬁl in healthy
m.2019.06.007
Table 1
Effects of sildenaﬁl and vinpocetine on isolated chorionic plate arteries obtained from healthy and early onset preeclamptic (PE) placentas.
pEC50 Emax
Control Sildenaﬁl Vinpocetine Control Sildenaﬁl Vinpocetine
Healthy 7·5 (7·9–7·3) 8·0 (8·3–7·6)⁎ 8·0 (8·3–7·6)⁎ 92 (86–110) 98 (87–112) 102 (97–111)
PE 7·6 (8·0–7·2) 7·6 (7·8–7·1) 7·5 (8·1–7·3) 85 (65–90) 97 (56–104) 90 (82–121)
Data are median (interquartile range). pEC50: -log10-transformed SNP concentrations at which the half-maximal response occurred. Emax: maximal effect of SNP (% of U46619
precontraction).
⁎ p b 0·05 vs. control (Friedman test for repeated measures).
Table 3
Clinical characteristics of healthy and early onset preeclamptic (PE) placentas used for sil-
denaﬁl transfer experiments.
6 E. Hitzerd et al. / EBioMedicine xxx (2019) xxxplacentas: sildenaﬁl facilitated the response to SNP. The fact that this
was not observed when adding SNP on top of sildenaﬁl to the foetal cir-
culation of the intact cotyledon setup implies that this effect is limited to
a selected subset of placental vessels. Also, it might well be that other
pathways than NO are important in regulation of vascular tone in
the whole cotyledon setup [15]. The non-selective PDE inhibitor
vinpocetine similarly potentiated SNP-induced vasorelaxation in
healthy isolated chorionic plate arteries. Yet, no such potentiating ef-
fectswere observedwith either sildenaﬁl or vinpocetine in isolated cho-
rionic plate arteries from PE placentas, suggesting that the potential
beneﬁcial effects of PDE inhibition are absent in this condition. In con-
trast, in ageing vessels, with upregulated PDE levels, sildenaﬁl and
vinpocetine did enhance SNP responses [40], thereby reversing the dis-
turbed endothelial function in this condition. In agreementwith the lack
of effect of sildenaﬁl in PE arteries, we did not detect PDE upregulation,
maternally or foetally, at the mRNA or protein level in PE placentas.
These data indicate that PDEupregulation is unlikely to underlie the dis-
turbed endothelial function that has been reported in PE.We could even
argue that the lost potentiating effect of sildenaﬁl in PE suggests a re-
duced signiﬁcance of the NO pathway in vasodilation in these arteries.
We stress that in the present studywe speciﬁcally evaluatedNO respon-
siveness, based on the assumption that the beneﬁcial effect of sildenaﬁl
would relate to its capacity to block PDE5 and hence should be seen in
the form of NO potentiation. We did not quantify endothelial dysfunc-
tion – this would have required the application of an endothelium-
dependent vasodilator. Furthermore, we studied foetoplacental vessels
rather than spiral arteries, although it is the latter that determine pla-
cental perfusion. Unfortunately, acquiring spiral arteries would have re-
quired a myometrial biopsy, which was not possible in our hospital.
However, even though the development of placental insufﬁciency starts
with aberrant remodelling of thematernal spiral arteries [10,11], subse-
quent changes in the foetoplacental vasculature have been described
[41,42], emphasising the relevance to study these vessels. Needless to
say, it cannot be said with certainty that the current ﬁndings also
apply to the maternal spiral arteries.
Sildenaﬁl decreased baseline pressure in isolated chorionic plate ar-
teries, both from healthy and PE placentas. This resembles the vasodila-
tor effect of sildenaﬁl reported by Walton et al. in the preconstricted
cotyledon setup [43]. Such a decrease was not observed for the non-
selective PDE inhibitor vinpocetine, nor for the highly selective PDE5 in-
hibitor tadalaﬁl (byWalton et al. [43]), despite itsmuch greater potencyTable 2
Placental vasoreactivity in healthy pregnancy and early onset preeclampsia (PE).
Parameter Healthy (n = 18) PE (n = 8)
Baseline pressure (mmHg) 34 (28–36) 23 (17–31)⁎
5-HT-induced pressure increase
(mmHg)



















Data are median (interquartile range).
⁎ p b 0·05 compared to healthy (Mann-Whitney U test).
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and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioversus sildenaﬁl. Yet, sildenaﬁl and vinpocetine identically potentiated
SNP in healthy chorionic plate arteries. Taken together, these data
strongly suggest that the acute sildenaﬁl-induced foetal dilation is unre-
lated to PDE5 inhibition. It may rather represent a non-speciﬁc effect of
sildenaﬁl. To what degree this still represents interference with PDEs
other than PDE5A remains to be investigated. Our data support the pres-
ence of PDE5A as the most abundant PDE in placental tissue, and addi-
tionally show expression of PDE10A, PDE4A and PDE1A at lower
levels. Only foetal PDE1A was altered in PE placentas, being actually
lower, i.e., opposing the concept of upregulated PDEs in PE. Importantly,
our data do support PE-related vascular changes, since baseline pressure
was lower in PE cotyledons, and 5-HT-induced constriction was
reduced.
Ex vivo cotyledon perfusion is a safe method to predict placental
transfer of drugs in vivo, avoiding foetal exposure [30]. In healthy
humanplacentas, Russo et al. demonstrated earlier that sildenaﬁl passes
the placental barrier, although they observed much higher F/M ratios
(0·90 vs. 0·37 here) [31]. Applying two different sildenaﬁl concentra-
tions, Russo et al. obtained levels in the foetal compartment correspond-
ing with approximately 13–14% of the total added amount of sildenaﬁl
[31], which is identical to what was observed in the current study
(16%). Yet, in their setup maternal steady-state levels were as high as
those in the foetal compartment, while in our setup, maternal levels
amounted to 43% of the total added amount of sildenaﬁl. To explain
the disappearance of sildenaﬁl (~40% in our setup versus ~70% in the
Russo paper), one has to assume that the drug is eithermetabolised, ad-
heres to tubing, and/or accumulates in tissue. Both Russo et al. and the
present study observed that ~45% of sildenaﬁl adhered to tubing.
Russo et al. did not observe metabolism, and given the fact that the
sum of the percentage adhered to tubing plus the percentages of intact
sildenaﬁl in maternal and foetal compartments in our setup equalled
the total added amount, our data also do not support metabolism, nor
signiﬁcant accumulation of sildenaﬁl in tissue. Conversely, Russo et al.
observed signiﬁcant tissue accumulation, absolute tissue levels being
identical at the two applied sildenaﬁl concentrations, despite the fact
that these concentrations differed 10-fold. This implies that their tissue
levels were up to 30-fold higher than those in the maternalHealthy PE
1 2 3 4 5 6 1 2
Maternal age (y) 36 31 24 36 38 39 30 26
Parity 1 1 1 1 3 1 0 0
Caucasian ethnicity yes no yes no no yes no yes
Body mass index (kg/m2) 24·6 27·3 27·8 20·8 29 24·7 28·5 23·1
Smoking no no no no no no no no
Highest DBP (mmHg) 75 86 80 80 75 80 120 109
Gestational age (weeks) 39·0 38·0 38·5 38·6 39·1 39·0 32·0 31·4
Mode of delivery CS CS CS CS CS CS CS CS
Foetal Sex M M M M F F M M
Birth weight (g) 4325 3475 3420 4010 3815 2940 1150 1460
Birth weight (centile) 96 76 55 89 83 16 0 6
Placental weight (g) 784 550 581 659 825 618 348 339
DPB = diastolic blood pressure; CS = caesarean section; M =male; F = female.
lafella, et al., Placental effects and transfer of sildenaﬁl in healthy
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Fig. 2. Placental transfer of sildenaﬁl in healthy and PE placentas. Panels a and b, concentration of sildenaﬁl in thematernal (closed symbols) and the foetal circulation (open symbols) in six
healthy (a) and two PE (b) placentas. Data are mean ± SEM. Panel c, F/M ratio of sildenaﬁl in individual healthy (grey circles) and PE placentas (black squares).
7E. Hitzerd et al. / EBioMedicine xxx (2019) xxxcompartment. In the present study, tissue levels (per g tissue), at most
corresponding with a few percent of the added amount of sildenaﬁl,
would have equalled the maternal levels (per mL). Hence, the much
lowermaternal levels in the Russo study appear to be entirely due to tis-
sue accumulation of sildenaﬁl, a phenomenon which was not observed
in the current study. At this stage we are not aware of data supporting
tissue accumulation of sildenaﬁl.
Towhat degree albumin (present in the perfusion buffer in the study
by Russo et al., but not in our study) determines tissue accumulation is
unknown. Sildenaﬁl binds plasma proteins for ~95%, which in vivo
inﬂuences the concentrations in the maternal and foetal circulations.
However, mimicking physiological protein concentrations in the
ex vivo experimental set-up remains very difﬁcult, since this does not
only concern albumin, but also other drug-binding proteins like α1-
acid glycoprotein and α-fetoprotein [30]. The concentrations of these
proteins vary betweenmaternal and foetal circulations, changewith ad-
vancing gestational age, andmight be altered by conditions like PE [44].
Importantly, the presence or absence of albumin should not affect the F/
M ratio of the free drug concentration at steady state [30]. Unfortu-
nately, to our knowledge, no data on sildenaﬁl concentrations in cord
blood and maternal plasma of pregnant women are currently available
in the literature, making it impossible to compare the observed
ex vivo transfer ratio to the actual in vivo situation.
Of interest, the transfer ratio of sildenaﬁl in the two preterm PE pla-
centas were the highest of all perfused placentas, whilst the general as-
sumption is that placental drug transport increases throughout
gestation [45]. Although preterm non-PE placentas would have been
the appropriate control for the PE placentas, these data indicate that in
PE conditions placental transfer of sildenaﬁl could be enhanced at anPlease cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebioearly stage. Naturally, these results need to be interpreted with caution,
since unfortunately the group size is very limited. This is due to the fact
that it is very challenging to successfully perfuse preterm placentas, and
especially PE placentas. Hence, extending the PE group, or including
preterm healthy placentas to study the effect of gestational age on sil-
denaﬁl transfer was not feasible. Notably, the mean measured concen-
tration of sildenaﬁl at t = 0 in the maternal circulation was higher in
the healthy placentas compared to the PE ones. This seems to be due
to measurement variability, as a similar variation is shown by Russo
et al. [31] However, we believe that the starting concentration is of no
inﬂuence to the F/M ratio, since it has been shown that even a 10-fold
difference in starting concentration produced similar ratios [31].
Clinical studies reported inconclusive results with sildenaﬁl in the
treatment of PE. In a small observational clinical trial sildenaﬁl im-
proved foetal growth in ten women with pregnancies complicated by
early FGR [46], although another study reported no effect on foetal out-
come nor prolongation of pregnancy [47]. Recently, the large multina-
tional randomised controlled STRIDER trials evaluating the effects of
sildenaﬁl versus placebo on pregnancy outcome in women with severe
placental insufﬁciency were halted prematurely [25]. Interim analysis
showed no improvement on foetal outcome in two cohorts [27,29]
and there was an increased incidence of pulmonary hypertension of
the new-born in the treatment group of the Dutch cohort [28,29].
Given the fact that sildenaﬁl passes the placenta, it might have had un-
wanted effects in the foetus, e.g. on lungdevelopment. One of the vascu-
lar changes that is associated with pulmonary hypertension is a lower
percentage of peripheral lung vessels, as frequently seen in foetuses
with a congenital diaphragmatic hernia (CDH) [48]. Russo et al. showed
in a rabbit model that, although sildenaﬁl exposure during pregnancylafella, et al., Placental effects and transfer of sildenaﬁl in healthy
m.2019.06.007
Fig. 3.mRNA expression. qPCR analysis of placental biopsies from the maternal (black bars) and foetal side (white bars) of 12 healthy and seven PE placentas. Data (mean ± SEM) are
expressed as fold change versus the maternal side biopsies of healthy controls. Panels a-d represent data for eNOS, iNOS, PDE5A and PDE1A. *p b 0·05; **p b 0·01 (Mann-Whitney U
test or Wilcoxon matched pairs test).
8 E. Hitzerd et al. / EBioMedicine xxx (2019) xxxsigniﬁcantly increased the percentage of peripheral lung vessels in off-
spring with CDH, it had the opposite effect in healthy foetuses without
CDH, as it signiﬁcantly reduced the percentage of peripheral
lung vessels compared to placebo treated animals [48]. Furthermore,
although sildenaﬁl treatment attenuated wall thickening of
peripheral pulmonary vessels in CDH, it has been shown to increase
muscularisation of the small pulmonary vessels in mice without CDH
[49]. Excessive muscularisation of the foetal pulmonary vasculature
could lead to an increased lumen diameter, thereby increasing vascular
resistance. Another possibility could be that, since sildenaﬁl reduces
pulmonary vascular resistance in the foetus [48], its placental transfer
resulted in acute withdrawal problems after birth in a high-risk group
already prone to develop pulmonary hypertension, as treatment was
not continued in the neonates. To avoid any unwanted effects on the
foetus, neonatal continuation of sildenaﬁl treatment might have been
an option. The use of the potent and highly selective PDE5A inhibitor
tadalaﬁl could also provide a better option than sildenaﬁl, since it has
a longer half-life and is less likely to pass the placenta [43]. However,
this needs to be further studied in placental transfer experiments, also
given the lack of maturation of the CYP3A pathway in neonates that is
crucial for tadalaﬁl metabolism [50].
In conclusion, in contrast to the general belief, we were unable to
demonstrate selective PDE upregulation in PE, nor did sildenaﬁl poten-
tiate NO in PE placentas. It did so in healthy placentas, and the absence
of this potentiation in PE suggests that interference at other levels than
PDE5might be required to improve endothelial dysfunction in this con-
dition, e.g. with sGC activators or stimulators. Importantly, we con-
ﬁrmed the previously described direct vasodilation induced by
sildenaﬁl, and observed that this is unrelated to PDE5 inhibition. Fur-
thermore, our data reveal the possibility that sildenaﬁl could reachPlease cite this article as: E. Hitzerd, M. Broekhuizen, K.M. Mirabito Co
and preeclamptic conditions, EBioMedicine, https://doi.org/10.1016/j.ebiohigher foetal levels during preterm PE treatment. To what degree in-
creased placental transfer and/or PDE5-independent effects of sildenaﬁl
may have contributed to its deleterious consequences in the STRIDER
trial remains to be determined. We stress that when considering a
drug for treatment during pregnancy, its placental transfer, preferably
per trimester of gestation, should be investigated ﬁrst.Funding sources
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